Aims/hypothesis Previous studies have shown an inverse association between soluble thrombomodulin (sTM) and incident CHD, but there is a lack of data on the association between sTM and type 2 diabetes. Since CHD and type 2 diabetes share many risk factors, the aim of this study was to assess whether elevated sTM levels are associated with a lower incidence of type 2 diabetes. Materials and methods A case-cohort study was performed in initially healthy middle-aged men and women based on data from the Monitoring of Trends and Determinants in Cardiovascular Disease/Cooperative Health Research in the Region of Augsburg (MONICA/KORA) studies conducted between 1984 and 1998. Levels of sTM were measured with an ELISA in serum samples from 138 men and 86 women who developed type 2 diabetes during follow-up (cases) and 534 men and 446 women who did not develop type 2 diabetes (non-cases).
Introduction
Thrombomodulin is a transmembrane protein that plays a major role in intravascular coagulation. It is an endothelial cell surface receptor for thrombin and functions as an anticoagulant through formation of a thrombin-thrombomodulin complex. This complex inhibits fibrin formation and platelet activation and accelerates protein C activation. In turn, activated protein C binds to platelet surface protein S, where it degrades factor VIIIa and factor Va, thereby inhibiting further formation of thrombin [1] .
Thrombomodulin is not only found bound to endothelial cells, soluble forms of thrombomodulin (sTM) are also present in the circulation. Up to seven molecular subspecies of sTM have been reported, the relative proportions of which appear to differ between diabetes patients and healthy control subjects [2] . Although sTM fragments have anticoagulant activity, their physiological role is unknown. Regulation of sTM concentrations occurs at several levels, including thrombomodulin production by endothelial cells, release of cell-bound thrombomodulin by endothelial injury, cleavage in response to production of proteases and protein clearance. Cellular production and release into the circulation may depend on immune activation and endothelial dysfunction, which have been suggested to represent the underlying causes (or 'common soil') of type 2 diabetes and CHD [3, 4] . Subjects with chronic diseases that are related to inflammation and endothelial dysfunction, such as atherosclerotic arterial diseases and type 2 diabetes, have increased levels of sTM [5, 6] . By contrast, in the prospective Atherosclerosis Risk in Communities (ARIC) study, levels of sTM were inversely associated with the risk of CHD [6] . It has been suggested that a prothrombotic state and endothelial dysfunction could enhance the risk of type 2 diabetes [7] . Thus, as a vasoprotective molecule, thrombomodulin may be involved in the pathophysiology of type 2 diabetes. The aim of the present study was to determine whether elevated concentrations of sTM are associated with a decreased risk of type 2 diabetes.
Subjects and methods
We conducted a case-cohort study using data from the population-based Monitoring of Trends and Determinants in Cardiovascular Disease/Cooperative Health Research in the Region of Augsburg (MONICA/KORA) cohort study. The study design has been described previously [8] ; all subjects provided written informed consent. The source population was stratified by sex and survey and then a subcohort was drawn at random within each stratum. Contrary to previous reports, this subcohort comprised only 1,025 subjects, and the present study included only incident cases that occurred between 1984 and 1998. Cases with self-reported incident diabetes in one of the follow-up questionnaires were validated by a questionnaire mailed to the treating physician or medical chart review. For deceased subjects without a previously reported diagnosis of diabetes, hospital records were searched for and/or the last treating physician was asked whether the patient had a history of diabetes. If the participant had diabetes, the type of diabetes and date of diagnosis were ascertained. The present analysis comprised 1,204 participants (138 men, 86 women with incident type 2 diabetes, 534 men, 446 women without incident type 2 diabetes). The follow-up time (mean ± SD) for the study population was 8.0±4.0 years.
Methods used to assess demographic, lifestyle and clinical characteristics and markers of inflammation have been described elsewhere in detail ( [8] and references therein). Non-fasting blood samples were collected from all participants, and all samples were stored at −80°C until analysis. Serum samples were thawed and refrozen twice before analysis of sTM. Levels of sTM were measured in serum using an ELISA (Diaclone, Besançon, France). The intraand inter-assay CVs were 10.3 and 16.8%, respectively.
Means ± SEM were calculated for sTM using the SAS procedure SURVEYREG, which estimated SEMs appropriate for the sampling scheme. Tests for differences were also based on these procedures. Cox proportional hazards analysis was used to assess the association between sTM and incident type 2 diabetes. Because of the case-cohort design, SEMs were corrected using an SAS macro with a 'sampling weight' approach developed by Barlow et al. ( [8] and references therein). Results are presented as hazard ratios (HRs) and 95% CIs per 1 SD increase in sTM in the subcohort, and p values are based on robust variance estimates using the Barlow macro. For all statistical analyses, a p value of less than 0.05 was considered statistically significant. All evaluations were performed with the statistical software package SAS (Version 8.02 for Unix; SAS Institute, Cary, NC, USA).
Results
Baseline characteristics of cases and non-cases are described in Electronic supplementary material (ESM) Table 1 . The mean (±SEM) unadjusted sTM levels were 4.7± 0.12 ng/ml in subjects with incident type 2 diabetes (cases) and 4.6±0.08 ng/ml in non-cases. Levels of sTM were significantly correlated with other markers of subclinical inflammation and endothelial dysfunction and with clinical parameters (Table 1) . Associations between sTM and lifestyle factors, drug use and comorbidities have been reported [9] and are shown in ESM Table 2 . After adjustment for age, sex, survey, BMI, smoking status, alcohol consumption, physical activity, systolic BP, ratio of total cholesterol:HDL-cholesterol, parental history of diabetes, C-reactive protein (CRP), IL-6, IL-18, soluble intercellular adhesion molecule-1 (sICAM-1) and soluble E-selectin (sE-selectin), mean levels (±SEM) of sTM were significantly lower in cases than in non-cases (4.1±0.18 vs 4.7±0.07, p=0.008).
In Cox proportional hazards models (Table 2) , sTM was inversely associated with incident type 2 diabetes after adjustment for classical risk factors for diabetes (model 2) or for other markers of inflammation and endothelial dysfunction (model 3). Addition of sE-selectin or sICAM-1 to the model containing age, sex and survey as covariables had the greatest effect on the observed HRs. The strongest inverse association between sTM and type 2 diabetes was observed in the fully adjusted model, which included classical risk factors for diabetes and other markers of inflammation and endothelial dysfunction (model 4). In this model, a 1 SD increment in sTM was associated with a 27% decrease in the risk of type 2 diabetes. HRs for the association between sTM and type 2 diabetes were only slightly lower in men than in women, but results were only significant in men, possibly as a result of the smaller number of incident cases in women (p=0.79 for sex interaction). Further adjustment for use of lipid-lowering medication did not affect the results, while additional adjustment for use of antihypertensive medication produced somewhat lower HRs in women (data not shown). Subgroup analyses in subjects with available data on WHR and waist circumference (130 cases, 542 non-cases) revealed that adjustment for WHR instead of BMI led to similar results. Adjustment for waist circumference instead of BMI led to slightly higher HRs; however, associations between sTM and type 2 diabetes remained significant in models 2 and 4 (data not shown). Exclusion of subjects with prevalent myocardial infarction, angina pectoris or stroke or incident myocardial infarction during follow-up (n=138) produced slightly lower HRs in men and slightly higher HRs in women (data not shown).
Discussion
In this population-based sample of middle-aged German men and women we have shown for the first time that elevated levels of sTM are associated with a decreased risk of type 2 diabetes after multivariable adjustment for classical diabetes risk factors and/or markers of inflammation and endothelial dysfunction. Type 2 diabetes was not significantly associated with sTM in the unadjusted model, but, consistent with previous results [9] , sTM levels were positively associated with diabetes risk factors and other markers of inflammation and endothelial dysfunction, most of which were elevated in subjects with increased diabetes risk [8] . Adjustment for these confounders could be expected to lower the HR for the association between sTM and type 2 diabetes risk and thus revealed an inverse association.
Our data may appear counterintuitive as previous crosssectional studies reported elevated sTM concentrations in patients with type 2 diabetes [5, 6] . However, similar results have been obtained in studies on cardiovascular and cerebrovascular diseases. Patients with CHD may have higher sTM levels, but in the prospective ARIC study, it was lower instead of higher sTM concentrations that predicted CHD [6 and references therein]. Another study showed that elevated sTM levels predicted mortality in patients with previous stroke, whereas elevated levels of sTM were associated with lower stroke prevalence when only individuals without a history of vascular disease were analysed [10] .
As endothelial thrombomodulin production, release of cell-bound thrombomodulin by endothelial injury or proteases and protein clearance probably all help to regulate sTM concentrations in the circulation, these epidemiological findings are difficult to interpret. It is conceivable that high circulating sTM in healthy individuals mainly reflects thrombomodulin production on endothelial cells and thus indicates an intact anticoagulant and vasoprotective state, so that decreased sTM concentrations in otherwise healthy individuals would indicate endothelial disturbances and an increased risk for the development of type 2 diabetes, CHD or stroke. In subjects with type 2 diabetes or CHD, subclinical inflammation and endothelial dysfunction could lead to a considerable increase in the pool of sTM fragments by cell injury, and a proinflammatory milieu including increased protease activities, which could obscure decreases in cellular thrombomodulin production. It can be argued that subjects who will later develop type 2 diabetes or CHD already suffer from subclinical inflammation many years before disease manifestation, but this level of immune activation is certainly less pronounced and may not be sufficient to impair the antithrombotic and anticoagulant activity of thrombomodulin.
Taken together, our results demonstrate that, in an initially healthy population-based cohort, sTM concentrations in the circulation and type 2 diabetes risk are inversely associated when adjustment is made for multiple confounders. The precise mechanisms responsible for this finding are not entirely clear. Further research is required to elucidate the mechanisms involved in regulating sTM concentrations, the impact of diseases on the relative proportions of sTM fragment types in the circulation, and the antithrombotic activity of these sTM forms.
